DPP-728 HCl

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: DPP-728 HCl
• 英文别名: 6-[2-[[2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl]amino]ethylamino]pyridine-3-carbonitrile;dihydrochloride
• 化学式: C15H20Cl2N6O
• 分子量: 371.3
• InChiKey: VNACOBVZDCLAEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.31
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  105
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• Cyanopyrrolidine derivatives
  申请人：——

  公开号：US20040072892A1

  公开（公告）日：2004-04-15

  A cyanopyrrolidine derivative represented by Formula (1): 1 [wherein R 1 is a halogen atom, a hydroxyl group, an alkoxy group having 1 to 5 carbon atoms or an alkyl group having 1 to 5 carbon atoms, R 2 is a hydrogen atom, a halogen atom, a hydroxyl group, an alkoxy group having 1 to 5 carbon atoms or an alkyl group having 1 to 5 carbon atoms, or R 1 and R 2 together form an oxo, a hydroxyimino group, an alkoxyimino group having 1 to 5 carbon atoms or an alkylidene group having 1 to 5 carbon atoms, R 3 and R 4 are each a hydrogen atom, a halogen atom, a hydroxyl group, an alkoxy group having 1 to 5 carbon atoms or an alkyl group having 1 to 5 carbon atoms, or R 3 and R 4 together form an oxo, a hydroxyimino group, an alkoxyimino group having 1 to 5 carbon atoms or an alkylidene group having 1 to 5 carbon atoms, X is an oxygen atom or a sulfur atom, Y is —CR 5 R 6 — (wherein R 5 and R 6 are the same or different, and are each a hydrogen atom, a halogen atom, an optionally substituted alkyl group having 1 to 10 carbon atoms or an optionally substituted alkenyl group having 2 to 10 carbon atoms), or —CR 7 R 8 —CR 9 R 10 — (wherein R 7 , R 8 , R 9 and R 10 are the same or different, and each a hydrogen atom, a halogen atom or an optionally substituted alkyl group having 1 to 10 carbon atoms, or R 7 and R 9 together with the carbon atom to which they are attached form an optionally substituted cycloalkyl group having 3 to 8 carbon atoms, an optionally substituted cycloalkenyl group having 4 to 8 carbon atoms, an optionally substituted bicycloalkyl group having 5 to 10 carbon atoms, or an optionally substituted bicycloalkenyl group having 5 to 10 carbon atoms) and Z is a hydrogen atom or an optionally substituted alkyl group having 1 to 10 carbon atoms, or Y and Z together with the nitrogen atom to which they are attached form an optionally substituted cyclic amino group having 2 to 10 carbon atoms], or a pharmaceutically acceptable salt thereof.

  一种由式（1）表示的氰基吡咯烷衍生物：1［其中R1是卤素原子，羟基，具有1至5个碳原子的烷氧基或具有1至5个碳原子的烷基，R2是氢原子，卤素原子，羟基，具有1至5个碳原子的烷氧基或具有1至5个碳原子的烷基，或R1和R2一起形成氧代，羟肟基，具有1至5个碳原子的烷氧肟基或具有1至5个碳原子的烷基亚甲基，R3和R4分别是氢原子，卤素原子，羟基，具有1至5个碳原子的烷氧基或具有1至5个碳原子的烷基，或R3和R4一起形成氧代，羟肟基，具有1至5个碳原子的烷氧肟基或具有1至5个碳原子的烷基亚甲基，X是氧原子或硫原子，Y是- CR5R6-（其中R5和R6相同或不同，且均为氢原子，卤素原子，具有1至10个碳原子的可选取代烷基或具有2至10个碳原子的可选取代烯基），或-CR7R8-CR9R10-（其中R7，R8，R9和R10相同或不同，且均为氢原子，卤素原子或具有1至10个碳原子的可选取代烷基，或R7和R9与它们附着的碳原子一起形成具有3至8个碳原子的可选取代环烷基，具有4至8个碳原子的可选取代环烯基，具有5至10个碳原子的可选取代双环烷基或具有5至10个碳原子的可选取代双环烯基），Z是氢原子或具有1至10个碳原子的可选取代烷基，或Y和Z与它们附着的氮原子一起形成具有2至10个碳原子的可选取代环氨基，或其药学上可接受的盐。
• CYANOPYRROLIDINE DERIVATIVES
  申请人：Fukushima Hiroshi

  公开号：US20070112059A1

  公开（公告）日：2007-05-17

  Cyanopyrrolidine compound represented by Formula (1): Wherein the substituents are as defined herein. The compounds inhibit dipeptidyl peptidase IV.

  公式（1）所代表的是Cyanopyrrolidine化合物：其中取代基如本文所定义。这些化合物抑制二肽基肽酶IV。
• Use of organic compounds
  申请人：——

  公开号：US20010016586A1

  公开（公告）日：2001-08-23

  The invention relates to the use of a hypolipidemic agent or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention or delay of the progression to overt diabetes, especially type 2, prevention or reduction of microvascular complications (eg, retinopathy, neurophathy, nephropathy), prevention or reduction of excessive cardiovascular morbidity (eg, myocardial infarction, arterial occlusive disease, atherosclerosis and stroke) and cardiovascular mortality, prevention of cancer and reduction of cancer deaths. Additionally, the invention relates to the use of a treatment for diseases and conditions that are associated with IGM, IGT or IFG.

  本发明涉及一种降血脂药剂或其药学上可接受的盐用于制造一种药物，以预防或延缓明显糖尿病（尤其是 2 型糖尿病）的发展，预防或减少微血管并发症（如视网膜病变、神经病变、肾病），预防或减少过高的心血管发病率（如心肌梗塞、动脉闭塞症、动脉粥样硬化）、预防或减少微血管并发症（如视网膜病变、神经病变、肾病变），预防或减少过多的心血管发病率（如心肌梗塞、动脉闭塞性疾病、动脉粥样硬化和中风）和心血管死亡率，预防癌症和减少癌症死亡。此外，本发明还涉及一种治疗与 IGM、IGT 或 IFG 相关的疾病和病症的方法。
• Combination of organic compounds
  申请人：——

  公开号：US20040002519A1

  公开（公告）日：2004-01-01

  The present invention relates to a combination, especially a pharmaceutical composition, comprising as active ingredients (i) a HMG-CoA reductase inhibitor or a or a pharmaceutically acceptable salt thereof; (ii) (a) an insulin secretion enhancer or a pharmaceutically acceptable salt thereof or (b) an insulin sensitizer or a pharmaceutically acceptable salt thereof; and, in case of a pharmaceutical composition, a pharmaceutically acceptable carrier.

  本发明涉及一种组合物，特别是一种药物组合物，其活性成分包括 (i) HMG-CoA 还原酶抑制剂或其药学上可接受的盐； (ii) (a) 胰岛素分泌促进剂或其药学上可接受的盐或 (b) 胰岛素增敏剂或其药学上可接受的盐；以及 在药物组合物的情况下，药学上可接受的载体。
• Use of compounds
  申请人：Guitard Christiane

  公开号：US20050043362A1

  公开（公告）日：2005-02-24

  The invention relates to the use of a hypolipidemic agent or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention or delay of the progression to overt diabetes, especially type 2, prevention or reduction of microvascular complications (eg, retinopathy, neurophathy, nephropathy), prevention or reduction of excessive cardiovascular morbidity (eg, myocardial infarction, arterial occlusive disease, atherosclerosis and stroke) and cardiovascular mortality, prevention of cancer and reduction of cancer deaths. Additionally, the invention relates to the use of a treatment for diseases and conditions that are associated with IGM, IGT or IFG.

  本发明涉及一种降血脂药剂或其药学上可接受的盐用于制造一种药物，以预防或延缓明显糖尿病（尤其是 2 型糖尿病）的发展，预防或减少微血管并发症（如视网膜病变、神经病变、肾病），预防或减少过高的心血管发病率（如心肌梗塞、动脉闭塞症、动脉粥样硬化）、预防或减少微血管并发症（如视网膜病变、神经病变、肾病变），预防或减少过多的心血管发病率（如心肌梗塞、动脉闭塞性疾病、动脉粥样硬化和中风）和心血管死亡率，预防癌症和减少癌症死亡。此外，本发明还涉及一种治疗与 IGM、IGT 或 IFG 相关的疾病和病症的方法。